Six candidate variants identified, of which 2 have previously characterized tumorigenic roles: (a) Increased expression of SMOX is associated with gastric cancer, and (b) SYTL3 encodes proteins which interact with RAB27 and deregulation of this pathway is associated with bladder cancer. Here, SMOX is linked to urinary bladder carcinoma.